PUBLISHER: DataM Intelligence | PRODUCT CODE: 1560787
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1560787
Global Intranasal Drug Delivery Market - 2024 - 2031
Report Overview
Global Intranasal Drug Delivery Market reached US$ 11.2 billion in 2023 and is expected to reach US$ 20.7 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.
Intranasal drug delivery is a method of administering medications through the nasal cavity. This route leverages the rich vascularization of the nasal mucosa, allowing drugs to be absorbed directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver.
It offers a non-invasive and convenient alternative for delivering various medications, including systemic drugs, vaccines, and treatments for local conditions like nasal congestion and allergies. The rapid absorption and onset of action make intranasal drug delivery particularly useful for conditions that require quick relief, such as migraines and pain.
Market Dynamics: Drivers & Restraints
Increasing preference for non-invasive drug administration methods
The global intranasal drug delivery market is driven by the growing preference for non-invasive methods, offering quick onset of action and convenience. This method is particularly beneficial for drugs requiring rapid absorption, such as in emergency settings or treating central nervous system disorders. The convenience and improved patient compliance of intranasal delivery are also boosting its adoption, especially among populations with difficulty with oral or injectable forms, such as pediatric and geriatric patients.
For instance, in July 2024, researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer's disease and dementia. The study, published in Science Translational Medicine, introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.
Limited absorption
The global intranasal drug delivery market faces challenges due to local irritation and limited absorption through the nasal mucosa. Certain drugs can cause discomfort and inconsistent absorption due to nasal anatomy and mucociliary clearance rates. These challenges limit the effectiveness and acceptance of intranasal drug delivery for medications requiring precise dosing and consistent absorption.
Market Segment Analysis
The global intranasal drug delivery market is segmented based on type, container type, application, distribution channel, and region.
The nasal spray from the type segment accounted for approximately 43.3% of the intranasal drug delivery market share
The nasal spray from the type segment accounted for approximately 43.3%. Nasal sprays are a popular method for administering various medications in the intranasal drug delivery market. They deliver a fine mist of medication directly into the nasal cavity, allowing rapid absorption into the bloodstream. This is particularly useful for quick-onset drugs like migraines, nasal congestion, and allergic rhinitis, as well as emergencies like opioid overdose. Nasal sprays are non-invasive and easy to use, making them a preferred alternative to injections or oral medications.
For instance, in October 2023, Otrivin Nasal Mist, a new generation of nasal spray, was launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis, and sinusitis. The innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology to dispense a full but gentle mist that evenly covers inflamed areas, with no dripping at the back of the nose and throat.
Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased awareness and improved healthcare facilities. Government initiatives and favorable reimbursement policies are also contributing to this growth. Asia is expected to experience high growth, with China and India dominating due to large investments, a rising population, and government funding.
For instance, in April 2024, Amneal Pharmaceuticals announced the availability of its Over-the-Counter Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent is manufactured in the U.S. and is used to treat drug overdose from opioids like heroin, fentanyl, and prescription opioid medications. The FDA has approved the medication.
Market Segmentation
By Type
Nasal Spray
Nasal Drops
Nasal Gel
Nasal Powder
By Container Type
Pressurized Container
Non-pressurized Container
By Application
Allergic and Non-allergic Rhinitis
Nasal Congestion
Sinusitis
Asthma
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include AstraZeneca, Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc, Aegis Therapeutics LLC among others.
Key Developments
In November 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities by adding a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action.
Why Purchase the Report?
To visualize the global intranasal drug delivery market segmentation based on type, container type, application, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the intranasal drug delivery market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global intranasal drug delivery market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Container Type
- 3.3. Snippet by Application
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing preference for non-invasive drug administration methods
- 4.1.1.2. Rise in the prevalence of chronic diseases
- 4.1.2. Restraints
- 4.1.2.1. Limited absorption
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. PESTLE Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Type
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
- 6.2. Nasal Spray*
- 6.2.1. Introduction
- 6.3. Nasal Drops
- 6.4. Nasal Gel
- 6.5. Nasal Powder
7. By Container Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 7.2. Market Attractiveness Index, By Container Type
- 7.3. Pressurized Container*
- 7.3.1. Introduction
- 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.4. Non-pressurized Container
8. By Application
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Allergic and Non-allergic Rhinitis*
- 8.2.1. Introduction
- 8.3. Nasal Congestion
- 8.4. Sinusitis
- 8.5. Asthma
- 8.6. Others
9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.7.1. The U.S.
- 10.2.7.2. Canada
- 10.2.7.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.7.1. Germany
- 10.3.7.2. UK
- 10.3.7.3. France
- 10.3.7.4. Italy
- 10.3.7.5. Spain
- 10.3.7.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.7.1. Brazil
- 10.4.7.2. Argentina
- 10.4.7.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.7.1. China
- 10.5.7.2. India
- 10.5.7.3. Japan
- 10.5.7.4. South Korea
- 10.5.7.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
12. Company Profiles
- 12.1. AstraZeneca*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Baxter International, Inc
- 12.3. Becton, Dickinson, and Company
- 12.4. GlaxoSmithKline PLC
- 12.5. Johnson & Johnson
- 12.6. Novartis AG
- 12.7. Pfizer Inc
- 12.8. Valeant Pharmaceuticals International, Inc
- 12.9. Merck & Co., Inc
- 12.10. Aegis Therapeutics LLC (*LIST NOT EXHAUSTIVE)
13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
